SASKATCHEWAN
FIRAZYR is covered by the Saskatchewan Drug Formulary (Exception Drug Status Program)
Eligibility
For FIRAZYR to be eligible for coverage by the Saskatchewan Drug Formulary, prescribers must submit a request under the Exception Drug Status Program of the Saskatchewan Drug Plan and the request must be approved before the patient fills the prescription. Deductibles may apply. For more information concerning the reimbursement process, contact OnePath®.
Reimbursement Criteria
We are pleased to inform you that FIRAZYR (icatibant acetate) is reimbursed in Saskatchewan for your hereditary angioedema (HAE) patients who meet the following criteria:
For the treatment of acute attacks of HAE in adults with lab confirmed C1-esterase inhibitor deficiency (type I or type II) if the following conditions are met:
- Treatment of non-laryngeal attacks of at least moderate severity, OR
- Treatment of acute laryngeal attacks
Notes:
- Limited to a single dose for self-administration per attack
- Prescribed by physicians with experience in the treatment of HAE
- Maximum quantity dispensed at one time is two (2) doses
OnePath® Patient Support Program will help navigate insurance coverage and access reimbursement to medication through private and public insurance companies.
Source: Saskatchewan Drug Formulary. Exception Drug Status Program – Appendix A.
http://formulary.drugplan.ehealthsask.ca/PDFs/APPENDIXA.pdf